RxDoctor Payments Data

Casey Gashti, MD

Nephrology · Chicago, ILNPI 1285762252

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,880 of the $73,866 with a category attached, or 64.8%. Nxstage Medical, Inc. accounts for 85.3% of it on its own, with 14 other manufacturers making up the rest. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,866in general payments, 2019–2025

Across 109 payments — averaging $677.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nxstage Medical, Inc.$63K
  • Fresenius USA Marketing, Inc.$7K
  • Amgen$3K
  • AstraZeneca$136
  • Aurinia Pharma U.S., Inc.$129
  • Calliditas Therapeutics US Inc.$93
  • plus $438 from 9 others

What the payments were for

  • Consulting fees$13,08818%
  • Speaking & faculty fees$47,88065%
  • Travel & lodging$9,50513%
  • Food & beverage$3,3935%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,866 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$206,927
Medicare patients
467
Services billed
2,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex11$22,646
JardianceEmpagliflozin15$20,917
ProsolParenteral Amino Acid 20% No.126$3,076
Bumetanide17$1,818
Sevelamer Carbonate13$1,084
Nifedipine ErNifedipine15$651
Irbesartan13$435
Amlodipine Besylate43$405
Sodium Chloride0.9 % Sodium Chloride15$347
Valsartan12$285
Furosemide41$257
Losartan Potassium28$222
Lisinopril23$166
Carvedilol13$155
Allopurinol19$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$25$20,91715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →